Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Mcleod, R. Griffiths, G. Bigelow, J. Yingling (1982)
An automated version of the digit symbol substitution test (DSST)Behavior Research Methods & Instrumentation, 14
D. Jasinski, J. Pevnick, J. Griffith (1978)
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.Archives of general psychiatry, 35 4
S. Walsh, K. Preston, M. Stitzer, I. Liebson, G. Bigelow (1993)
Comparison of the acute effects of buprenorphine and methadone in non- dependent humansNIDA research monograph
Jasinski Dr, Haertzen Ca, J. Henningfield, Rolley Johnson, Makhzoumi Hm, K. Miyasato (1982)
Progress report of the NIDA Addiction Research Center.NIDA research monograph, 41
E. Strain, K. Preston, I. Liebson, G. Bigelow (1992)
Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.The Journal of pharmacology and experimental therapeutics, 261 3
N. Mello, J. Mendelson (1980)
Buprenorphine suppresses heroin use by heroin addicts.Science, 207 4431
S. Heishman, M. Stitzer, G. Bigelow, I. Liebson (1989)
Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.The Journal of pharmacology and experimental therapeutics, 248 1
Rolley Johnson, J. Jaffe, P. Fudala (1992)
A controlled trial of buprenorphine treatment for opioid dependence.JAMA, 267 20
A. Cowan, J. Lewis, I. Macfarlane (1977)
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENTBritish Journal of Pharmacology, 60
E. Strain, K. Preston, I. Liebson, G. Bigelow (1995)
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.The Journal of pharmacology and experimental therapeutics, 272 2
A. Takemori, M. Ikeda, P. Portoghese (1986)
The μ, κ and δ properties of various opioid agonists☆European Journal of Pharmacology, 123
C. Haertzen (1974)
An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales.
M. Aceto (1984)
Characterization of prototypical opioid antagonists, agonist-antagonists, and agonists in the morphine-dependent rhesus monkeyNeuropeptides, 5
M. Stitzer, G. Bigelow, I. Liebson (1984)
Single‐day methadone dose alteration: Detectability and symptomsClinical Pharmacology & Therapeutics, 36
L. Amass, Warren Bickel, S. Higgins, G. Badger (1994)
Alternate-day dosing during buprenorphine treatment of opioid dependence.Life sciences, 54 17
K. Kirby, M. Stitzer, S. Heishman (1990)
Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II.The Journal of pharmacology and experimental therapeutics, 255 2
K. Preston, G. Bigelow, I. Liebson (1988)
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.NIDA research monograph, 76
D. Jasinski, W. Martin, R. Hoeldtke (1971)
Studies of the dependence‐producing properties of GPA‐1657, profadol, and propiram in manClinical Pharmacology & Therapeutics, 12
Jasinski Dr, J. Re, Hickey Je, C. Haertzen, J. Henningfield, K. Kumor (1983)
Progress report of the NIDA Addiction Research Center, Baltimore, Maryland, 1982.NIDA research monograph, 43
E. Strain, K. Preston, I. Liebson, G. Bigelow (1993)
Precipitated withdrawal by pentazocine in methadone-maintained volunteers.The Journal of pharmacology and experimental therapeutics, 267 2
J. Dum, A. Herz (1981)
In vivo RECEPTOR BINDING OF THE OPIATE PARTIAL AGONIST, BUPRENORPHINE, CORRELATED WITH ITS AGONISTIC AND ANTAGONISTIC ACTIONSBritish Journal of Pharmacology, 74
E. Strain, M. Stitzer, I. Liebson, George Bigelow (1994)
Comparison of buprenorphine and methadone in the treatment of opioid dependence.The American journal of psychiatry, 151 7
C. Haertzen, M. Meketon, N. Hooks (1970)
Subjective experiences produced by the withdrawal of opiates.The British journal of addiction to alcohol and other drugs, 65 3
Warren Bickel, M. Stitzer, I. Liebson, G. Bigelow (1988)
Acute physical dependence in man: effects of naloxone after brief morphine exposure.The Journal of pharmacology and experimental therapeutics, 244 1
K. Preston, G. Bigelow, I. Liebson (1989)
Antagonist effects of nalbuphine in opioid-dependent human volunteers.The Journal of pharmacology and experimental therapeutics, 248 3
W. Bickel, M. Stitzer, G. Bigelow, I. Liebson, D. Jasinski, Rolley Johnson (1988)
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addictsClinical Pharmacology & Therapeutics, 43
P. Fudala, J. Jaffe, E. Dax, Rolley Johnson (1990)
Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate‐day administration and abrupt withdrawalClinical Pharmacology & Therapeutics, 47
W. Martin, D. Jasinski, C. Haertzen, D. Kay, B. Jones, P. Mansky, R. Carpenter (1973)
Methadone--a reevaluation.Archives of general psychiatry, 28 2
K. Preston, G. Bigelow, I. Liebson (1988)
Buprenorphine and naloxone alone and in combination in opioid-dependent humansPsychopharmacology, 94
N. Mello, J. Mendelson, J. Kuehnle (1982)
Buprenorphine effects on human heroin self-administration: an operant analysis.The Journal of pharmacology and experimental therapeutics, 223 1
L. Kolb, C. Himmelsbach (1938)
CLINICAL STUDIES OF DRUG ADDICTION, IIIAmerican Journal of Psychiatry, 94
S. Walsh, K. Preston, M. Stitzer, E. Cone, G. Bigelow (1994)
Clinical pharmacology of buprenorphine: Ceiling effects at high dosesClinical Pharmacology & Therapeutics, 55
K. Verebely, J. Volavka, S. Mulé, R. Resnick (1975)
Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatmentClinical Pharmacology & Therapeutics, 18
W. Martin, C. Eades, J. Thompson, R. Huppler, P. Gilbert (1976)
The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.The Journal of pharmacology and experimental therapeutics, 197 3
Warren Bickel, M. Stitzer, G. Bigelow, I. Liebson, Donald Jasinski, Rolley Johnson (1988)
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.The Journal of pharmacology and experimental therapeutics, 247 1
213 119 119 3 3 S. L. Walsh H. L. June K. J. Schuh K. L. Preston G. E. Bigelow M. L. Stitzer Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Science Johns Hopkins University School of Medicine 21224 Baltimore MD USA Departments of Psychology and Medical Neurobiology Indiana University-Purdue University Indianapolis Indiana USA Clinical Trials Branch, Addiction Research Center National Institute on Drug Abuse Baltimore Maryland USA Abstract Buprenorphine, a partial mu opioid agonist, is an experimental medication under development for the treatment of opioid dependence as an alternative to methadone maintenance. The present study examined the relationship between level of opioid physical dependence and response to buprenorphine administration as part of a program to develop procedures for transferring patients from methadone to buprenorphine treatment. This laboratory study characterized the agonist and antagonist effects of acute doses of buprenorphine and methadone in subjects maintained on either 30 ( n =7) or 60 ( n =6) mg/day oral methadone. Test doses of placebo (sl. and PO), methadone (15, 30, and 60 mg PO) and buprenorphine (2, 4, and 8 mg sl.) were administered to volunteers residing on a closed residential unit. Subjective, physiological, observer-rated, and cognitive/psychomotor measures were collected for 6.5 h after test doses. Test doses of methadone, but not buprenorphine, constricted pupils and produced dose-related increases on subjective report measures reflecting opioid agonist drug effects. Agonist effects of methadone were more prominent in the 30 mg than in the 60 mg methadone maintenance condition. Buprenorphine, but not methadone, precipitated opioid withdrawal signs and symptoms that were more prominent in the 60 mg than in the 30 mg methadone maintenance condition. These findings suggest that abrupt transition from methadone to buprenorphine may produce patient discomfort that is positively related to both methadone maintenance dose and buprenorphine transition dose.
Psychopharmacology – Springer Journals
Published: Jun 1, 1995
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.